The short answer
The added bleeding risk from Curcuma longa with prasugrel is uncertain. Review the exact product, dose and your bleeding history with your prescriber.
What this answer covers
Oral Curcuma longa with oral prasugrel hydrochloride tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
- Supplement or preparation
- Curcuma longa
- Medication ingredient
- prasugrel
What the evidence shows
A small study of turmeric alone and with aspirin found no clinically relevant overall added platelet or coagulation effect. It did not test prasugrel or rule out uncommon bleeding.
Consider the prescribed treatment
Prasugrel is an antiplatelet medicine supplied in hydrochloride tablets. It can cause serious bleeding, but stopping it prematurely after stent treatment can also cause serious harm. Its platelet effect lasts longer than the active metabolite remains in blood, so a short gap between doses is not an established way to prevent supplement-related bleeding.
Review the exact product
Review the preparation, dose and additional ingredients such as piperine. Food turmeric, purified curcumin and concentrated multi-ingredient extracts are different exposures. Separate product toxicity does not establish a measured bleeding, liver or GI interaction for every preparation.
Know when to get help
Seek urgent care for bleeding that will not stop, vomiting blood or black, tarry stools. Tell your prescriber about the full supplement and medicine list. Do not stop prescribed antiplatelet treatment on your own to accommodate a supplement; ask the treating team to make a plan.
Evidence and practical considerations
Side effects & toxicity
An increased bleeding rate specifically from Curcuma longa with prasugrel has not been established.
- Exact scope
- Oral Curcuma longa with oral prasugrel hydrochloride tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable. with Exact prasugrel RxCUI613391 IN. Current label identifies racemic hydrochloride tablets expressing5/10mg prasugrel-equivalent doses; active metabolite exposure is distinguished from parent ingredient.
- Medication form and route
- Oral
What remains uncertain
- Available supplement-only and other-drug studies do not establish exact-pair clinical harm or exclude rare events. No validated preventive spacing interval.
Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.
Read the supporting source summaries
Source 1: Current prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Prescription oral oral prasugrel hydrochloride tablets users; short human pharmacology studies where described.
Serious bleeding risk; premature discontinuation may increase stent thrombosis, MI or death. Rifampin did not change active-metabolite exposure; label expects no important CYP-induction effect.
How this applies: Exact current product label. Exact prasugrel RxCUI613391 IN. Current label identifies racemic hydrochloride tablets expressing5/10mg prasugrel-equivalent doses; active metabolite exposure is distinguished from parent ingredient.
Exact salt-to-IN bridge from product label; no herb-specific bleeding rate. Original rifampin study retained modest platelet differences beyond simplified label summary.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Approximately 25 healthy volunteers assigned per herb.
No clinically relevant overall platelet/coagulation change or added aspirin inhibition. No significant bleeding manifestations reported.
How this applies: Indirect for oral prasugrel hydrochloride tablets co-use; exact preparation and endpoint retained.
Abstract-only; small short study, preparation detail incomplete. Occasional individual platelet responses do not establish clinical bleeding; rare harm or different products not excluded.
Source 3: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
prasugrel is IN.
How this applies: Exact identity.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: 80cdfb82e9243b04
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.